Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on serious rare genetic skin diseases and vascular malformations that lack FDA-approved therapies. Its QTORIN platform delivers topical formulations designed for targeted skin penetration; lead candidate QTORIN rapamycin is in late-stage development for microcystic lymphatic malformations. The company aims to commercialize first-in-disease treatments for lifelong genodermatoses and related conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -9.5 | — |
| Q3 2025 | 0 | — | -11.3 | — |
| Q4 2025 | 0 | — | -12.7 | — |
| Q1 2026 | 0 | — | -15.8 | — |
| Q2 2026 | 0 | — | -21.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: BlackLine, Inc. (BL), Preformed Line Products Company (PLPC), Mesoblast Limited (MESO), S&T Bancorp, Inc. (STBA), Alignment Healthcare, Inc. (ALHC), Hope Bancorp, Inc. (HOPE)